Notice of Change to PAR-23-024 -Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional) (NOT-DK-23-020) National Institute of Diabetes and Digestive and Kidney Diseases. Include a link to your My Bibliography complete list of publications and be sure the data are complete and up to date. Supplement request should be submitted electronically. Refer to NIH's Early Stage Investigator policies for information about what awards impact ESI status. In Section H: Indirect Costs, enter your institutional "indirect cost type," "indirect cost rate," "indirect cost base" and "funds requested.". See Section VIII. Applications will compete for available funds with all other recommended applications. Request an extension to your ESI eligibility period through eRA Commons using the ESI Extension request button located in the Education section of your Personal Profile. The focus should be on the importance of the questions or challenges. Plan to utilize the project infrastructure (i.e., research and structure) to support career-enhancing research opportunities for diverse junior, early- and mid-career researchers. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day. The award contains two components, a mentored (K99) phase that can last up to 2 years and an independent (R00) phase, which will have a duration of 3 years. Research Strategy: MIRA applications should not use the typical Research Strategy headings of Significance, Innovation, and Approach. With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage and implement the proposed clinical trial and meet milestones and timelines? Your First R01 Grant Application We are particularly interested in applications from physician-scientists. All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Is experiencing a serious personal health issue or illness and/or debilitating condition. Reviewers will consider each of the review criteria below in the determination of scientific merit, however, individual review criterion scores will not be assigned. Applications are reviewed in study sections (Scientific Review Group, SRG). Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information or potential to advance scientific knowledge or clinical practice? See Section III. NIHTurning Discovery Into Health If you are early in your career you might also be able to participate in our Early Career Reviewer program. The award can provide support for certain basic shared resources, including clinical components, which facilitate the total research effort. If your status isn't correct, contact the, Once you apply for and receive certain NIH awards, you no longer qualify as anESI. NIGMS staff will verify that the MIRA research effort requirement is met by using theOther supportdocumentation and will exclude support for which the purpose is education, training or enhancing workforce diversity. To what extent do the efforts described in the Plan for Enhancing Diverse Perspectives further the significance of the project? NIGMS strongly encourages potential applicants to confer with the program officer managing awards in their specific research area at least 6 weeks prior to submission for advice on the suitability of the proposed research for NIGMS. The Stephen I. Katz Early Stage Investigator Research Grant Program ReWARD Frequently Asked Questions - nigms.nih.gov Renewals: ESI MIRA recipients will be eligible to renew their MIRAs through MIRA NOFOs not limited to ESIs, e.g., through PAR-22-180 and reissuances of it. First Competitive Renewal of R01 Applications From Former NIDDK ESIs NIDDK seeks to encourage the stable integration of early career researchers into the scientific research workforce. The mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases is to support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases. Instead, a total requested direct cost amount for each budget period, including requests for equipment purchase, is required. NIGMS will not consider funding future individual PD/PI or multiple PD/PI research grant applications on which a MIRA PD/PI is listed as the PD/PI or MPI during the MIRA funded project period, except for of those in the bulleted list in Section I under Overlap during peer review. Thus, NIGMS will not accept applications for grants not on the list of exempted awards from MIRA PDs/PIs unless the earliest start date of the grant is after the end date of the MIRA grant. Projects that involve novel technology or tool development, and have the potential to significantly accelerate research fields. The investigators have primary authorities and responsibilities to define research objectives and approaches, and to plan, conduct, analyze, and publish results, interpretations and conclusions of their studies. Agency Contacts of this NOFO) before submitting an ESI MIRA application. The PD/PI is required to devote at least 51% of their total research effort to this award. See more tips for avoiding common errors. Email:support@grants.gov, Sailaja Koduri, Ph.D.National Institute of General Medical Sciences (NIGMS)Email: sailaja.koduri@nih.gov, Maqsood Wani, Ph.D.Center for Scientific Review (CSR)Email: wanimaqs@csr.nih.gov, Lisa MoellerNational Institute of General Medical Sciences (NIGMS)Email: moellerl@mail.nih.gov. TheOER Glossaryand the SF424 (R&R) Application Guide provide details on these application types. Frequently Asked Questions for the NHLBI Clinical Ancillary Studies FOA WebMAILING ADDRESS: Office of State Inspector General | P.O. NIH This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement. Projects that propose the novel application of methods, technologies, or conceptual approaches from outside biomedical science to a research problem in the NIAMS mission area. NIH After the PD/PI's ESI eligibility has expired, they may be eligible to apply to the MIRA for Established and New Investigators as a new investigator. This grant is not appropriate for conducting research with human subjects for the collection of preliminary data (clinical or preclinical) or the collection of prospective data to support the rationale for a clinical trial. This new all-time high level of support for ESIs represents a 7.2% increase over FY The demands of childbirth and subsequent primary caregiving responsibilities may necessitate changes to career goals and alter researchers career trajectories, depriving the scientific workforce of an important source of talent and undermining NIH's investment in promising avenues of new research. NIGMS will not accept applications from MIRA recipients for awards that would begin prior to the original project period end date of the MIRA, with the exceptions in the bulleted list above in the "Overlap During Peer Review" section. Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional) National Department of Health and Human Services, Grants & Funding: The NIAMS Extramural Program, Types of Funding Mechanisms (Activity Codes), NIAMS Core Centers for Clinical Research (CCCR) - FAQs, PA-16-161"NIH Exploratory/Developmental Research Grant Program (Parent R21)", NOT-OD-09-013, "Revised New and Early Stage Investigator Policies, Office of Extramural Research: Small Business Innovation Research (SBIR) and Small Business Technology (STTR) Programs, https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html, Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed), Administrative Supplements to Promote Diversity in Research and Development Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed), Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp - Clinical Trial Not Allowed), Notice of Special Interest: Administrative Supplements to Promote Research Continuity and Retention of NIH Mentored Career Development (K) Award Recipients and Scholars, Notice of Special Interest (NOSI): Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards, NRSA Stipends, Tuition/Fees, and Institutional Allowance, NRSA Stipends, Tuition/Fees, and Training Related Expenses, U.S. Department of Health and Human Services. 318-286-3599. As applicable for the proposed research program, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score. In making funding decisions on R21 applications, NIAMS will place a higher priority on projects that are: Projects that will be considered a lower priority include: Contact: Refer to contact information for the relevant NIAMS Supported Scientific AreaDuration: 2 yearsBudget Cap: $275,000 direct costs spread over two yearsApplications Due: Standard dates Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate? The NIAMS welcomes applications to the NIH Loan Repayment Program. In addition, when NIs or ESIs receive their first grant they are encouraged to maintain contact with their Program Official who can be an excellent resource during this critical stage of your research career. This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. ESIs are new investigators who are within 10 years of completing either their terminal research degree or their medical residency (whichever is later) at the time they apply for R01 grants. U.S. citizenship or permanent resident status is required. Research Strategy (6-page limit) to include: 2. If the proposed research involves human subjects and/or NIH-defined clinical research, are the plans to address: (1) the protection of human subjects from research risks, and (2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified? We are interested in applications that meet the eligibility requirements for either the Clinical Research Program or the Pediatric Research Program. New & Early Stage Investigators - NIDDK - National Institute of